4.4 Review

cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer

Journal

CURRENT CANCER DRUG TARGETS
Volume 23, Issue 5, Pages 354-362

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009623666221115095114

Keywords

cGAS-STING; lung cancer; immunotherapy; combination therapy; STING agonist; cGAMP

Categories

Ask authors/readers for more resources

Immunotherapy has revolutionized lung cancer treatment and improved overall survival for advanced patients, but many are still resistant. The cGAS-STING pathway has shown potential in overcoming resistance and enhancing antitumor immunity, making it a promising target for new therapies.
Immunotherapy has completely changed the treatment pattern of lung cancer and significantly prolonged the overall survival of patients, especially for advanced patients. However, a large number of lung cancer patients are unable to benefit from immunotherapy, which forces us to find new therapeutic targets to overcome drug resistance to immunotherapy. Cyclical GMP-AMP synthetase (cGAS) recognizes cytoplasmic DNA and promotes the formation of cyclical GMP-AMP (cGAMP), activates stimulator of interferon genes (STING), then induces the expression of varieties pro-inflammatory cytokines and chemokines, and then promotes the cross-presentation of dendritic cells (DCs) and initiates tumor-specific CD8+T cell response, showing great potential to overcome resistance and enhance antitumor immunity. In this review, we describe recent advances in the biological function,activation mode, and current applications of cGAS-STING pathway in lung cancer therapy. We also describe the mechanisms of the inactivation of cGAS-STING pathway in lung cancer cells, hoping to promote the progress of immunotherapy of lung cancer by targeting cGAS-STING pathway.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available